周二,RBC Capital Markets调整了对Intra-Cellular Therapies股票的立场,将这家生物制药公司的评级从"跑赢大市"下调至"与大市同步"。然而,该公司将股票目标价从之前的108美元上调至132美元。这一调整是在上周强生公司 (JNJ)宣布计划以约146亿美元收购Intra-Cellular Therapies之后做出的。
Modern life makes us tired, right? But research from societies in Africa and South America suggests people in the ancient ...